This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.
News|Articles|March 28, 2025 (Updated: March 28, 2025)
5 pediatric FDA decisions to watch for in Q2 2025
A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.
Advertisement
Advertisement
As we transition into the second quarter of 2025, pediatric health care providers are keeping a close eye on a slate of anticipated FDA decisions that could reshape the treatment landscape for children and adolescents.
Related to this article
XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.
Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Jonathan Miller, MD, discusses earlier HPV vaccination, individualized conversations with hesitant families, and strategies to improve vaccine uptake.
Jonathan Miller, MD, discusses factors behind lagging HPV vaccination rates and how pediatricians can address common parent concerns.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
A clinician-reported misinformation tracker at Children's Hospital of Philadelphia found vaccines accounted for 53.8% of 234 entries and informed education on 28 topics.
Advertisement
Advertisement